---
company: Doximity, Inc.
ticker: DOCS
form: 8-K
filed: 2026-05-13
accession: 0001516513-26-000017
source: https://www.sec.gov/Archives/edgar/data/1516513/000151651326000017/
---

# Doximity (DOCS) earnings release, May 13, 2026

Doximity, Inc. (DOCS) · Form 8-K, Item 2.02 · Filed 2026-05-13 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1516513/000151651326000017/)

Doximity Announces Fourth Quarter and Fiscal Year 2026 Financial Results

Fiscal year 2026 total revenues of $644.9 million, up 13% year-over-year

Fiscal year 2026 operating cash flows of $326.5 million, up 19% year-over-year

Fiscal year 2026 free cash flow of $317.5 million, up 19% year-over-year

SAN FRANCISCO, Calif., May 13, 2026

-- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 fourth quarter and fiscal year ended March 31, 2026.

“We’re thrilled to announce that we reached a new engagement record of over 800,000 active prescribers using our workflow tools in Q4. Nearly half of those providers used our clinical AI last quarter, while our prompts per user nearly doubled from January to April alone,” said Jeff Tangney, co-founder and CEO of Doximity.

“Our new partnerships with Aledade and Photon build on that momentum, bringing our Clinical AI Suite to thousands of independent practices and enabling seamless in-workflow prescribing for the first time. I'm also thrilled to welcome Matt Sonefeldt as our new CFO and Dr. Steve Zatz as our new President, two exceptional leaders whose experience and relationships will be instrumental as we continue to scale.”

Fiscal 2026 Fourth Quarter Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended March 31, 2025.

• Revenue:

Revenue of $145.4 million, versus $138.3 million, an increase of 5% year-over-year.

• Net income and non-GAAP net income:

Net income of $19.1 million, versus $62.5 million, representing a margin of 13.1%, versus 45.2%. Non-GAAP net income of $49.8 million, versus $77.7 million, representing a margin of 34.2%, versus 56.2%.

• Adjusted EBITDA:

Adjusted EBITDA of $65.8 million, versus $69.7 million, a decrease of 6% year-over-year, representing adjusted EBITDA margins of 45.3%, versus 50.4%.

• Diluted net income per share and non-GAAP diluted net income per share:

Diluted net income per share was $0.10, versus $0.31, while non-GAAP diluted net income per share was $0.26, versus $0.38.

• Operating cash flow and free cash flow

: Operating cash flow of $109.5 million, versus $98.5 million, an increase of 11% year-over-year, and free cash flow of $107.3 million, versus $97.0 million, an increase of 11% year-over-year.

Fiscal Year

2026 Financial Highlights

All comparisons, unless otherwise noted, are to the fiscal year ended March 31, 2025.

• Revenue:

Revenue of $644.9 million, versus $570.4 million, an increase of 13% year-over-year.

• Net income and non-GAAP net income:

Net income of $196.1 million, versus $223.2 million, representing a margin of 30.4%, versus 39.1%. Non-GAAP net income of $302.7 million, versus $286.1 million, representing a margin of 46.9%, versus 50.2%.

• Adjusted EBITDA:

Adjusted EBITDA of $357.8 million, versus $313.8 million, an increase of 14%, representing adjusted EBITDA margins of 55.5%, versus 55.0%.

• Diluted net income per share and non-GAAP diluted net income per share:

Diluted net income per share was $0.98, versus $1.11, while non-GAAP diluted net income per share was $1.52, versus $1.42.

• Operating cash flow and free cash flow

: Operating cash flow of $326.5 million, versus $273.3 million, an increase of 19% year-over-year, and free cash flow of $317.5 million, versus $266.7 million, an increase of 19% year-over-year.¹

Financial Outlook

Doximity is providing guidance for its fiscal first quarter ending June 30, 2026 as follows:

• Revenue between $151 million and $152 million.

• Adjusted EBITDA between $68.5 million and $69.5 million.

Doximity is providing guidance for its fiscal year ending March 31, 2027 as follows:

• Revenue between $664 million and $676 million.

• Adjusted EBITDA between $323 million and $335 million.²

Conference Call Information

Doximity posted prepared remarks on its investor relations website at https://investors.doximity.com. Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com. The archived webcast will be available on the Company’s Investor Relations page shortly after the call.

About Doximity

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. With new AI-powered clinical reference and search capabilities, Doximity also helps doctors access trusted, peer-reviewed information and medical literature. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.

Forward-Looking Statements... (truncated)tegies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including (i) the timing and scope of anticipated stock repurchases; (ii) the impact of uncertainty in the current economic environment and macroeconomic uncertainty; (iii) our ability to retain existing members or add new members to our platform and maintain or grow their engagement with our platform; (iv) our ability to attract new customers or retain existing customers; (v) the impact of our prioritization of our members’ interests; (vi) breaches in our security measures or unauthorized access to members’ data; (vii) our ability to maintain or manage our growth, and other risks and factors that are beyond our control including, without limitation, those set forth in the section entitled “Risk Factors” in the Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2025. Additional information will be provided in our Annual Report on Form 10-K for the fiscal year ended March 31, 2026. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management’s beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations Contact:

Perry Gold ir@doximity.com

Media Contact:

Amanda Cox pr@doximity.com³

## Financial statements

### Income Statement (Three Months Ended March 31, — (unaudited))

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 | Fiscal Year Ended March 31, – 2026 | Fiscal Year Ended March 31, – 2025 |
|---|---:|---:|---:|---:|
| Revenue | 145,372 | 138,288 | 644,863 | 570,399 |
| Cost of revenue(1) | 19,407 | 14,467 | 70,326 | 55,874 |
| Gross profit | 125,965 | 123,821 | 574,537 | 514,525 |
| Operating expenses(1): | Research and development | 39,106 | 24,803 | 130,702 | 93,038 |
| Operating expenses(1): | Sales and marketing | 45,910 | 37,611 | 163,648 | 145,713 |
| Operating expenses(1): | General and administrative | 16,123 | 12,727 | 65,267 | 45,670 |
| Operating expenses(1): | Impairment charge |  |  |  | 2,304 |
| Operating expenses(1): | Total operating expenses | 101,139 | 75,141 | 359,617 | 286,725 |
| Operating expenses(1): | Income from operations | 24,826 | 48,680 | 214,920 | 227,800 |
| Operating expenses(1): | Other income, net | 7,295 | 9,714 | 35,085 | 35,774 |
| Operating expenses(1): | Income before income taxes | 32,121 | 58,394 | 250,005 | 263,574 |
| Operating expenses(1): | Provision for (benefit from) income taxes | 13,007 | -4,064 | 53,954 | 40,389 |
| Operating expenses(1): | Net income | 19,114 | 62,458 | 196,051 | 223,185 |
| Net income per share attributable to Class A and Class B common stockholders: | Basic | 0.1 | 0.33 | 1.05 | 1.19 |
| Net income per share attributable to Class A and Class B common stockholders: | Diluted | 0.1 | 0.31 | 0.98 | 1.11 |
| Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders: | Basic | 184,852 | 188,362 | 187,014 | 186,841 |
| Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders: | Diluted | 195,026 | 202,987 | 199,048 | 201,208 |

### Income Statement (Three Months Ended March 31, — (1) Cost of revenue and operating expenses include stock-based compensation expense as follows (in thousands):)

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 | Fiscal Year Ended March 31, – 2026 | Fiscal Year Ended March 31, – 2025 |
|---|---:|---:|---:|---:|
| Cost of revenue | 2,957 | 2,628 | 11,680 | 11,001 |
| Research and development | 15,994 | 4,792 | 46,159 | 19,394 |
| Sales and marketing | 11,253 | 6,442 | 39,397 | 26,323 |
| General and administrative | 6,538 | 4,198 | 24,391 | 15,668 |
| Total stock-based compensation expense | 36,742 | 18,060 | 121,627 | 72,386 |

### Income Statement (Three Months Ended March 31, — The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below: (in thousands))

| | Three Months Ended March 31, – 2026 – (unaudited) | Three Months Ended March 31, – 2025 – (unaudited) | Fiscal Year Ended March 31, – 2026 – (unaudited) | Fiscal Year Ended March 31, – 2025 – (unaudited) |
|---|---:|---:|---:|---:|
| Net income | 19,114 | 62,458 | 196,051 | 223,185 |
| Adjusted to exclude the following: | Acquisition and other related expenses |  |  | 1,616 |  |
| Adjusted to exclude the following: | Stock-based compensation | 36,742 | 18,060 | 121,627 | 72,386 |
| Adjusted to exclude the following: | Depreciation and amortization | 4,131 | 2,829 | 14,383 | 10,659 |
| Adjusted to exclude the following: | Provision for (benefit from) income taxes | 13,007 | -4,064 | 53,954 | 40,389 |
| Adjusted to exclude the following: | Impairment charge |  |  |  | 2,304 |
| Adjusted to exclude the following: | Change in fair value of contingent earn-out consideration liability | 79 | 167 | 417 | 680 |
| Adjusted to exclude the following: | Legal expenses | 40 |  | 4,853 |  |
| Adjusted to exclude the following: | Other income, net | -7,295 | -9,714 | -35,085 | -35,774 |
| Adjusted to exclude the following: | Adjusted EBITDA | 65,818 | 69,736 | 357,816 | 313,829 |
| Adjusted to exclude the following: | Revenue | 145,372 | 138,288 | 644,863 | 570,399 |
| Adjusted to exclude the following: | Net income margin | 13.1 | 45.2 | 30.4 | 39.1 |
| Adjusted to exclude the following: | Adjusted EBITDA margin | 45.3 | 50.4 | 55.5 | 55 |

### Income Statement (Three Months Ended March 31, — The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below: (in thousands))

| | Three Months Ended March 31, – 2026 – (unaudited) | Three Months Ended March 31, – 2025 – (unaudited) | Fiscal Year Ended March 31, – 2026 – (unaudited) | Fiscal Year Ended March 31, – 2025 – (unaudited) |
|---|---:|---:|---:|---:|
| GAAP cost of revenue | 19,407 | 14,467 | 70,326 | 55,874 |
| Adjusted to exclude the following: | Stock-based compensation | -2,957 | -2,628 | -11,680 | -11,001 |
| Adjusted to exclude the following: | Amortization of acquired intangibles | -935 |  | -935 |  |
| Adjusted to exclude the following: | Non-GAAP cost of revenue | 15,515 | 11,839 | 57,711 | 44,873 |
| Adjusted to exclude the following: | GAAP gross profit | 125,965 | 123,821 | 574,537 | 514,525 |
| Adjusted to exclude the following: | Stock-based compensation | 2,957 | 2,628 | 11,680 | 11,001 |
| Adjusted to exclude the following: | Amortization of acquired intangibles | 935 |  | 935 |  |
| Adjusted to exclude the following: | Non-GAAP gross profit | 129,857 | 126,449 | 587,152 | 525,526 |
| Adjusted to exclude the following: | GAAP gross margin | 86.7 | 89.5 | 89.1% | 90.2 |
| Adjusted to exclude the following: | Non-GAAP gross margin | 89.3 | 91.4 | 91.1% | 92.1 |
| Adjusted to exclude the following: | GAAP research and development expense | 39,106 | 24,803 | 130,702 | 93,038 |
| Adjusted to exclude the following: | Stock-based compensation | -15,994 | -4,792 | -46,159 | -19,394 |
| Adjusted to exclude the following: | Amortization of acquired intangibles |  |  | -1,558 |  |
| Adjusted to exclude the following: | Non-GAAP research and development expense | 23,112 | 20,011 | 82,985 | 73,644 |
| Adjusted to exclude the following: | GAAP sales and marketing expense | 45,910 | 37,611 | 163,648 | 145,713 |
| Adjusted to exclude the following: | Stock-based compensation | -11,253 | -6,442 | -39,397 | -26,323 |

### Income Statement (Three Months Ended March 31, — The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below: (in thousands))

| | Three Months Ended March 31, – 2026 – (unaudited) | Three Months Ended March 31, – 2025 – (unaudited) | Fiscal Year Ended March 31, – 2026 – (unaudited) | Fiscal Year Ended March 31, – 2025 – (unaudited) |
|---|---:|---:|---:|---:|
| GAAP operating expense | 101,139 | 75,141 | 359,617 | 286,725 |
| Adjusted to exclude the following: | Acquisition and other related expenses |  |  | -1,616 |  |
| Adjusted to exclude the following: | Stock-based compensation | -33,785 | -15,432 | -109,947 | -61,385 |
| Adjusted to exclude the following: | Amortization of acquired intangibles | -1,005 | -1,061 | -5,572 | -4,244 |
| Adjusted to exclude the following: | Change in fair value of contingent earn-out consideration liability | -79 | -167 | -417 | -680 |
| Adjusted to exclude the following: | Legal expenses | -40 |  | -4,853 |  |
| Adjusted to exclude the following: | Impairment charge |  |  |  | -2,304 |
| Adjusted to exclude the following: | Non-GAAP operating expense | 66,230 | 58,481 | 237,212 | 218,112 |
| Adjusted to exclude the following: | GAAP operating income | 24,826 | 48,680 | 214,920 | 227,800 |
| Adjusted to exclude the following: | Acquisition and other related expenses |  |  | 1,616 |  |
| Adjusted to exclude the following: | Stock-based compensation | 36,742 | 18,060 | 121,627 | 72,386 |
| Adjusted to exclude the following: | Amortization of acquired intangibles | 1,940 | 1,061 | 6,507 | 4,244 |
| Adjusted to exclude the following: | Change in fair value of contingent earn-out consideration liability | 79 | 167 | 417 | 680 |
| Adjusted to exclude the following: | Legal expenses | 40 |  | 4,853 |  |
| Adjusted to exclude the following: | Impairment charge |  |  |  | 2,304 |
| Adjusted to exclude the following: | Non-GAAP operating income | 63,627 | 67,968 | 349,940 | 307,414 |
| Adjusted to exclude the following: | GAAP net income | 19,114 | 62,458 | 196,051 | 223,185 |
| Adjusted to exclude the following: | Acquisition and other related expenses |  |  | 1,616 |  |
| Adjusted to exclude the following: | Stock-based compensation | 36,742 | 18,060 | 121,627 | 72,386 |
| Adjusted to exclude the following: | Amortization of acquired intangibles | 1,940 | 1,061 | 6,507 | 4,244 |
| Adjusted to exclude the following: | Change in fair value of contingent earn-out consideration liability | 79 | 167 | 417 | 680 |
| Adjusted to exclude the following: | Legal expenses | 40 |  | 4,853 |  |
| Adjusted to exclude the following: | Impairment charge |  |  |  | 2,304 |
| Adjusted to exclude the following: | Income tax effect of non-GAAP adjustments (1) | -8,148 | -4,050 | -28,354 | -16,719 |
| Adjusted to exclude the following: | Non-GAAP net income | 49,767 | 77,696 | 302,717 | 286,080 |
| Adjusted to exclude the following: | Non-GAAP net income margin | 34.2 | 56.2 | 46.9 | 50.2 |
| Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders: | Basic | 184,852 | 188,362 | 187,014 | 186,841 |
| Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders: | Diluted | 195,026 | 202,987 | 199,048 | 201,208 |
| Non-GAAP net income per share attributable to Class A and Class B stockholders: | Basic | 0.27 | 0.41 | 1.62 | 1.53 |
| Non-GAAP net income per share attributable to Class A and Class B stockholders: | Diluted | 0.26 | 0.38 | 1.52 | 1.42 |

### Balance Sheet (March 31, 2026 — (unaudited))

| | March 31, 2026 | March 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 219,178 | 209,614 |
| Current assets: | Marketable securities | 529,423 | 706,050 |
| Current assets: | Accounts receivable, net | 144,783 | 128,354 |
| Current assets: | Prepaid expenses and other current assets | 50,880 | 44,602 |
| Current assets: | Total current assets | 944,264 | 1,088,620 |
| Current assets: | Property and equipment, net | 18,080 | 13,656 |
| Current assets: | Deferred income tax assets | 31,984 | 60,014 |
| Current assets: | Operating lease right-of-use assets | 7,140 | 8,886 |
| Current assets: | Intangible assets, net | 35,325 | 23,072 |
| Current assets: | Goodwill | 84,973 | 67,940 |
| Current assets: | Other assets | 1,921 | 2,121 |
| Current assets: | Total assets | 1,123,687 | 1,264,309 |
| Current liabilities: | Accounts payable | 4,009 | 1,356 |
| Current liabilities: | Accrued expenses and other current liabilities | 42,804 | 38,405 |
| Current liabilities: | Deferred revenue, current | 106,050 | 114,285 |
| Current liabilities: | Operating lease liabilities, current | 2,110 | 2,211 |
| Current liabilities: | Total current liabilities | 154,973 | 156,257 |
| Current liabilities: | Deferred revenue, non-current | 400 | 280 |
| Current liabilities: | Operating lease liabilities, non-current | 8,075 | 10,185 |
| Current liabilities: | Contingent earn-out consideration liability, non-current |  | 5,579 |
| Current liabilities: | Other liabilities, non-current | 9,402 | 9,383 |
| Current liabilities: | Total liabilities | 172,850 | 181,684 |
| Stockholders' Equity | Common stock | 183 | 189 |
| Stockholders' Equity | Additional paid-in capital | 1,001,688 | 894,225 |

### Cash Flow (Three Months Ended March 31, — (unaudited))

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 | Fiscal Year Ended March 31, – 2026 | Fiscal Year Ended March 31, – 2025 |
|---|---:|---:|---:|---:|
| Cash flows from operating activities | Net income | 19,114 | 62,458 | 196,051 | 223,185 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Depreciation and amortization | 4,131 | 2,829 | 14,383 | 10,659 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Deferred income taxes | 32,138 | -13,788 | 32,138 | -11,592 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Stock-based compensation, net of amounts capitalized | 36,742 | 18,060 | 121,627 | 72,386 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Non-cash lease expense | 384 | 446 | 1,747 | 1,838 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Accretion of discount on marketable securities, net | -1,130 | -2,919 | -7,581 | -11,655 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Amortization of deferred contract costs | 4,207 | 3,423 | 13,478 | 9,967 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Impairment of long-lived assets |  |  |  | 2,304 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Other | 133 | -19 | 314 | 270 |
| Changes in operating assets and liabilities: | Accounts receivable | 11,720 | 9,258 | -16,879 | -27,206 |
| Changes in operating assets and liabilities: | Prepaid expenses and other assets | 1,105 | -18,489 | -8,272 | 2,762 |
| Changes in operating assets and liabilities: | Deferred contract costs | -3,231 | -2,982 | -14,490 | -12,051 |
| Changes in operating assets and liabilities: | Accounts payable, accrued expenses and other liabilities | -35,254 | -4,535 | 4,268 | -663 |
| Changes in operating assets and liabilities: | Deferred revenue | 39,969 | 45,295 | -8,115 | 15,210 |
| Changes in operating assets and liabilities: | Operating lease liabilities | -506 | -550 | -2,211 | -2,149 |
| Changes in operating assets and liabilities: | Net cash provided by operating activities | 109,522 | 98,487 | 326,458 | 273,265 |
| Cash flows from investing activities | Cash paid for acquisition |  |  | -26,528 |  |
| Cash flows from investing activities | Purchases of intangible assets |  |  | -62 |  |
| Cash flows from investing activities | Internal-use software development costs | -2,253 | -1,507 | -8,901 | -6,525 |
| Cash flows from investing activities | Purchases of marketable securities | -8,037 | -143,724 | -389,159 | -675,557 |
| Cash flows from investing activities | Maturities of marketable securities | 148,267 | 118,180 | 561,434 | 635,401 |
| Cash flows from investing activities | Sales of marketable securities |  | 2,578 | 10,386 | 17,383 |
| Cash flows from investing activities | Net cash provided by (used in) investing activities | 137,977 | -24,473 | 147,170 | -29,298 |
| Cash flows from financing activities | Proceeds from issuance of common stock upon exercise of stock options and common stock warrants | 2,767 | 5,827 | 9,784 | 19,732 |
| Cash flows from financing activities | Proceeds from issuance of common stock in connection with the employee stock purchase plan | 2,076 | 2,147 | 3,892 | 3,569 |
| Cash flows from financing activities | Taxes paid related to net share settlement of equity awards | -7,477 | -10,856 | -40,839 | -27,185 |
| Cash flows from financing activities | Repurchase of common stock | -90,525 | -26,788 | -431,652 | -120,293 |
| Cash flows from financing activities | Payment of contingent consideration related to a business combination |  |  | -5,249 | -5,470 |
| Cash flows from financing activities | Payment of excise taxes on share repurchases |  |  |  | -1,491 |
| Cash flows from financing activities | Net cash used in financing activities | -93,159 | -29,670 | -464,064 | -131,138 |
| Cash flows from financing activities | Net increase in cash and cash equivalents | 154,340 | 44,344 | 9,564 | 112,829 |
| Cash flows from financing activities | Cash and cash equivalents, beginning of period | 64,838 | 165,270 | 209,614 | 96,785 |
| Cash flows from financing activities | Cash and cash equivalents, end of period | 219,178 | 209,614 | 219,178 | 209,614 |
| Supplemental disclosures of cash flow information | Cash paid for taxes, net of refunds | 792 | 19,840 | 21,814 | 55,654 |

### Cash Flow (Three Months Ended March 31, — The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below: (in thousands))

| | Three Months Ended March 31, – 2026 – (unaudited) | Three Months Ended March 31, – 2025 – (unaudited) | Fiscal Year Ended March 31, – 2026 – (unaudited) | Fiscal Year Ended March 31, – 2025 – (unaudited) |
|---|---:|---:|---:|---:|
| Net cash provided by operating activities | 109,522 | 98,487 | 326,458 | 273,265 |
| Purchases of intangible assets |  |  | -62 |  |
| Internal-use software development costs | -2,253 | -1,507 | -8,901 | -6,525 |
| Free cash flow | 107,269 | 96,980 | 317,495 | 266,740 |
| Other cash flow components: | Net cash provided by (used in) investing activities | 137,977 | -24,473 | 147,170 | -29,298 |
| Other cash flow components: | Net cash used in financing activities | -93,159 | -29,670 | -464,064 | -131,138 |
